Mindset is developing next-generation psychedelic medicines and related manufacturing processes to help treat neuropsychiatric patients with unmet needs.
Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:
3 patent-pending new drug families drawing on novel chemical structures;
75 compounds synthesized with preclinical data demonstrating promising results; and
Synthesis process for psilocybin demonstrating clear benefits over known processes.
March 30, 2021Read More
March 23, 2021Read More
March 22, 2021Read More